BioCryst Cited for Double-Digit Upside as Takeover Candidate After $10B Crinetics Deal
BCRX•Vertex’s $10B acquisition of Crinetics at a significant premium has investors eyeing BioCryst as a takeover target with double-digit upside, driven by its clinical-stage rare disease inhibitor program. BioCryst’s market value trails the implied deal multiple, indicating room for a similar takeover premium.
1. Vertex’s $10B Crinetics Acquisition
Vertex agreed to acquire Crinetics for $10B, marking one of the largest rare disease buyouts this year. The deal valued Crinetics at a significant premium over its previous trading levels, underscoring the high multiples investors are willing to pay for late-stage pipeline assets.
2. BioCryst’s Takeover Speculation
Following the Crinetics transaction, BioCryst has seen renewed takeover chatter as its oral complement inhibitor candidates advance in clinical trials. Analysts note BioCryst’s market capitalization remains below the implied Crinetics multiple, suggesting potential for a similar premium-driven upside.
